Reme Mountifield
Overview
Explore the profile of Reme Mountifield including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Barnes A, Ooi S, Lynch K, Parthasarathy N, Bishara M, Gounder M, et al.
Dig Dis Sci
. 2022 Jun;
68(3):889-896.
PMID: 35687221
Background: The thiopurine medications are well established in the treatment of inflammatory bowel disease (IBD). There is significant variation in levels of toxic and therapeutic metabolites. Current data from small...
12.
Barnes A, Andrews J, Spizzo P, Mountifield R
JGH Open
. 2021 May;
5(5):585-589.
PMID: 34013059
Background And Aim: Medication nonadherence is common in patients with inflammatory bowel disease (IBD) and has been associated with worse outcomes. The coronavirus disease 2019 (COVID-19) pandemic led to significant...
13.
Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
Barnes A, Hofmann D, Hall L, Klebe S, Mountifield R
Ann Gastroenterol
. 2021 May;
34(3):447-448.
PMID: 33948072
Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old...
14.
Mountifield R
J Gastroenterol Hepatol
. 2021 Apr;
36 Suppl 1:25-26.
PMID: 33817852
No abstract available.
15.
Barnes A, Spizzo P, Mountifield R
Intern Med J
. 2020 Nov;
52(5):828-833.
PMID: 33197107
Background: Steroid exposure has been associated with poorer outcomes following colectomy in acute severe ulcerative colitis (ASUC). Aim: To examine the effect of prolonged oral corticosteroid therapy immediately prior to...
16.
Barnes A, Spizzo P, Mountifield R
Intern Med J
. 2020 Oct;
52(3):436-439.
PMID: 33009839
Background: Faecal calprotectin (FCP) is a highly sensitive non-invasive marker of intestinal inflammation that has evidence-based roles in outpatient diagnosis and management of inflammatory bowel disease. Aims: To examine indications...
17.
Barnes A, Mountifield R
Inflamm Bowel Dis
. 2020 Apr;
26(6):e53.
PMID: 32242614
No abstract available.
18.
Mountifield R
J Gastroenterol Hepatol
. 2018 Sep;
33 Suppl 3:30.
PMID: 30187552
No abstract available.
19.
Mountifield R
J Gastroenterol Hepatol
. 2018 Sep;
33 Suppl 3:18.
PMID: 30187546
No abstract available.
20.
Bryant R, Costello S, Schoeman S, Sathananthan D, Knight E, Lau S, et al.
J Gastroenterol Hepatol
. 2017 Aug;
33(3):599-607.
PMID: 28806471
Background And Aims: A "treat-to-target" approach has been proposed for ulcerative colitis (UC), with a target of combined clinical and endoscopic remission. The aim of the study was to evaluate...